The current COVID-19 global pandemic poses immense challenges to global health, largely
due to the difficulty to detect infection in the early stages of the disease, as well as the …

Determinants of protective immunity against SARS-CoV-2 infection require the development
of well-standardized, reproducible antibody assays to be utilized in concert with clinical trials …

Background Convalescent plasma (CP) is a potentially important therapy for coronavirus
disease 2019 (COVID-19). However, knowledge regarding neutralizing antibody (NAb) titers …

Background Characterizing the kinetics of the antibody response to severe acute respiratory
syndrome coronavirus 2 (SARS‐CoV‐2) is of critical importance to developing strategies …

Introduction The lack of approved specific therapeutic agents to treat coronavirus disease
(COVID‐19) associated with severe acute respiratory syndrome coronavirus 2 (SARS‐CoV …

COVID-19 convalescent plasma (CCP) is currently under investigation for both treatment
and post-exposure prophylaxis. The active component of CCP mediating improved outcome …

Background COVID-19 is a pandemic with no specific antiviral treatments or vaccines. The
urgent needs for exploring the neutralizing antibodies from patients with different clinical …

Since the emergence of SARS-CoV-2 numerous antibody assays have become available,
demonstrating different performance characteristics. This study focused on a quantitative …

Abstract Immunoglobulin (IG) lots (N= 176) released since March 2020 were tested for
SARS-CoV-2 neutralizing antibodies, with first positive results for September 2020 lots …

Background: Convalescent plasma is one of the treatment options for COVID-19 which is
currently being investigated in many clinical trials. Understanding of donor and product …